Customer No. 28880 A TRACT

Sheet 1

Translation is ettached

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0551-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

of 1

Complete if Known Application Number 10/811,200 Filing Date March 26, 2004 First Named Inventor Wayne L. Cody et al Art Unit 1614 Examiner Name Attorney Docket Number PC25562A

	U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Number-Kind Code ^{2 (Finowe)}	Publication Date MM-DD-YYYY	Name of Patantee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	Г	US-	1				
	1	US-					
		US-					
		US-					
	\vdash	US-					
	\vdash	US-					
		US-					
		US-	1				
	1	US-					
	-	US-					
		US-					
	\vdash	US-					
		US-	 				
	 	US-	1				
		US-	 				
	 	US-	1		1		
	├	US-	1				
	\vdash	US-	+				
		US-					

Examiner Initials*	Cite No.1	Foreign Patent Occument Country Code ³ "Number ⁴ "Gnd Code ⁸ (if known)	Publication Date	Name of Patantee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
			MM-DD-YYYY		
12		WO 02/088101	11/07/2002	Bhisetti, et al	
12		WO 97/09311	03/13/1997	Binggeli, et al	
	<u> </u>				
	_				

Examiner

EXAMINER Initial II reference considered, whether o'not classon is in configuration with IMPEP 650. These line through citission if not in configuration and more considered, which are only on the configuration to applicant. *Applicant's unique citistic edisplated in unique (optional). *See Kinds Codes of considered, Mortal Codes of the form with an examination of the code of code of the form with a code of code of the co

Introduction of elitations.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 33 USC, 122 and 37 CFR 1.14. This collection is estimated to take 7 about to complete. The Confidentiality processing and the Confidentiality is governed by 33 USC, 122 and 37 CFR 1.14. This collection is estimated to take 2 about to complete the Confidentiality and comments of the variety of the Confidentiality of the Confidentiali TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450.

If you need assistance in complating the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Customer No. 28880

Sheet 1

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S.DE PARTMENT OF COMMERCE ns are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act 071995...ne.sh Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

of 3

Complete if Known Application Number 10/811,200 Filing Date March 26, 2004 First Named Inventor Wayne L. Cody et al Art Unit Examiner Name Attorney Docket Number PC25562A

Date Considered

U. S. PATENT DOCUMENTS Cite No. Document Number Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document Pages,C olumns, Lines, Where vant Passagee or Relevant Figures Appear Number-Kind Code^{2 (Dino wa)} US- 6.051,712 04-18-2000 Hoffman-I a Roche Inc. ^{US-} 6,150,526 11-21-2000 Hoffman-La Roche Inc. 0-US-US-TIE. IIS. us-US US-US US-112 US-US US-

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign PatentD ocument Country Code ³ Number ⁴ 'Rind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Т
						T
iL	Г	WO03/093267 A1	11-13-2003	ACTE-LION		С
		WO00/64887 A1	11-02-2000	F. HOFFMAN		Г
$\neg \top$	I	WO02/076440 A2	10-03-2002	ELAN PHARM		
		WO00/64873 A1	11-02-2000	F. HOFFMAN		П
		WO01/74796 A1	10-11-2001	Dupont Pharm		Г
4		WO01/22964 A1	04-05-2001	Georgetown Un.,		↸

2/17/05 Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and n "EXAMINE: Initial a retire rock considered, whether or not citation as in conformance with MPEF 800. Draw line through citation if not in personance and not update. The conformance is conformance and not update to the conformance and not update

0.0

Translation is attached. The calcelor of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to Rie (and by the USPTO to process) an application. Confidentially is governed by 35 U.SC., 122 and 37 CFR 1.14. This coldicion is estimated to basis A you to complete, the control of the Company of the C

TO: Commissioner for Patente, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2. W No 75520

Sheet 2

MAY 2 1 2004 5

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S.DE PARTMENT OF COMMERCE

THANK Under the Paperwork Reducti nd to a collection of information unless it contains a valid OMB control numb Complete if Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) of 3

Application Number 10/811,200 Filing Date March 26, 2004 First Named Inventor Wayne L. Cody et al Art Unit Attorney Docket Number PC25562A

	U. S. PATENT DOCUMENTS						
Examiner Cite Initials* No.1	Cite	Document Number Number-Kind Code ^{7 (Ane set)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear		
	1						
		US-					
		US-					
		US-					
		Us-					
		US-					
	1	US-					
	-	US-					
		US-					
		US-					
		US-					
		US-					
	1	Us-					
		US-					
		US-					
	t	US-					
	T	US-					
	1	US-					
	<u> </u>	US-	1				
	+-	US-					

FOREIGN PATENT DOCUMENTS Foreign PatentD ocument Pages, Columns, Lines, Applicant of Cited Document Where Relevant Passages Or Relevant Figures Appear ۳ MM-DD-YYYY Country Code3 "Number 4 "Kind Code5 (if known) WO99/65867 A1 12-23-1999 DuPont Pharm... CL

Examiner

Signature

Date

Considered

A 1 / 0.5

Considered

A 2 / 0.5

Considered

A 1 /

Translation is attached.
This collection of inform Translation is statched.

USET to provide the property of the



PTOSBABB (IB-G3)

U.S. Patent and Trademark Office; U.S. DE PARTMENT OF COMMERCE

O required to respond to a collection of Information untess it contains a valid OMB control number.

Complete if Known

Application Number Substitute for form 1449/PTO INFORMATION DISCLOSURE | Filing Date March 26, 2004 STATEMENT BY APPLICANT First Named Inventor Wayne L. Cody et al Art Unit (Use as many sheets as necessary) Examiner Name Attorney Docket Number Sheet 3 PC25562A

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ce/		MARKI, H.P. ET AL., "Piperidine renin inhibitors: from leads to drug candidates", Il Farmaco (2001), VOL. 56, PAGES 21-27	
		OEFNER, C.; BINGGELI ET AL., "Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?", Chemistry & Biology 1999, Vol. 6, pages 127-131	
		GULLER, R.; BINGGELI et al., "Piperidine-Renin inhibitors Compounds With Improved Pysicochemical Properties", Bioorg. Mcd. Chem. Lett. 1999, Vol. 9, pages 1403-1408	
		VIEIRA, E.; BINGGELI et al., "Substituted Piperidines-Highly Potent Renin Inhibitors Due To Induced Fit Adaptation of The Active Site", Bioorg. Med. Chem. Lett. 1999, Vol. 9, pages 1397-1402	
		RAHUEL, J.; RASETTI et al., "Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin", Chemistry & Biology 2000, Vol. 7, pages 493-504	
W		BURSAVICH, M. G., et al., "The Mechanism of Reations Catalysed By The Serine Beta-Lactamases", Ogr. Lett. 2001, Vol. 3, No. 15 pages 2317-2320	
		:	

Examiner Signature	Chy	Date Considered	2/17/05
EXAMINER: II	itial if reference considered, whether or not citat	on is in conformance with MPEP 609. Draw line through c	itation if not in conformance and not

"EXAMINE: Initial Irreference considered, whether on a classion is in conformance with MPP 969. Drew the through classion if not in conformance and not considered. Include copy of this form which need communication to be applicate.

I applicants undue classion designation number (options). 2 Applicant is to piece a drew classion designation number (options). 2 Applicant is to piece a drew classion of established in section of the information is required to obtain or resista a benefit by the public which is to the (and by the USPTO. The collection of information is required by a CPL 18.5." The resistance of the conformation of the conformation application from the USPTO. There will vary depositing upon the individual case. Any comments on the amount of time by orangive locomplete in from any discussions for reducing the burden, should be sent to the Civil information Officer, IV. Sent and Tordeman Officer, P.O. Box 180, Alexandria, VA 22131-1460, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 180, Alexandria, VA 22313-1460, AV 23313-1460, AV 23313-14